MRI,Gene And Cognitive Performance Study of Patients With Cerebral White Matter Lesions(WMLs)
1 other identifier
observational
200
1 country
1
Brief Summary
The purpose of this study is:1)to observe topological organization in brain structural and functional networks in cerebral white matter lesion patients and to evaluate the association between impairment of cognitive function and cerebral structural and functional networks in those patients;2)to indicate the role of genetic factors in the occurrence and prognosis of cerebral white matter lesions
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
October 25, 2014
CompletedFirst Posted
Study publicly available on registry
October 28, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2019
CompletedDecember 14, 2015
December 1, 2015
1.9 years
October 25, 2014
December 11, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
MRI and cognitive function scale
up to 5 years after first assessment
Study Arms (2)
cerebral white matter lesions
patients with MRI confirmed cerebral white matter lesions
healthy volunteers
healthy volunteers 1:1 matched by age,sex and education years
Eligibility Criteria
patients with cerebral white matter lesions
You may qualify if:
- MRI diagnosis of cerebral white matter lesions Must be able to measure his(her) neuropsychologic function No severe stroke history and no physical disability Patients aged 40 to 85 Based on China's relevant laws, the patient himself agreed to participate in this study, a good compliance.Patients himself/herself must sign informed consent moreover
You may not qualify if:
- Unable to undergo examinations due to disturbances of consciousness or medical conditions Serious complications including severe heart failure, hepatic dysfunction, renal insufficiency,or shock AD,Parkinson's disease, malignant tumor, MS and other autoimmune diseases toxic and metabolic encephalopathy cerebral white matter lesions caused by CADASIL and other confirmed monogenic disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wei Wanglead
Study Sites (1)
Department of Neurology of Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Biospecimen
DNA extracted from whole blood sample
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wei Wang, Doctor
Tongji Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
October 25, 2014
First Posted
October 28, 2014
Study Start
March 1, 2014
Primary Completion
February 1, 2016
Study Completion
September 1, 2019
Last Updated
December 14, 2015
Record last verified: 2015-12